A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease - Related Studies

A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease

This study has been completed.

Study NCT00001341. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Neoplasm

2	Additional conditions recognized in this trial
		Neoplasms

3	Interventions listed in this trial
		ZD1694 (TOMUDEX)

4	Additional drug interventions recognized in this trial
		Raltitrexed

5	More general drug interventions related to this trial
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Enzyme Inhibitors
		Folic Acid Antagonists
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		National Cancer Institute (NCI)